Abstracts from the XXth International Symposium on Medicinal Chemistry: August 31 - September 4 [2008], Vienna, Austria
Gespeichert in:
| Format: | Tagungsbericht Buch |
|---|---|
| Sprache: | Undetermined |
| Veröffentlicht: |
Barcelona [u.a.]
Prous Science
2008
|
| Schriftenreihe: | Drugs of the future
33 : Suppl. A |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | Einzelaufnahme eines Zeitschr.-Bd. |
| Beschreibung: | 341 S. Ill., graph. Darst. |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV035101291 | ||
| 003 | DE-604 | ||
| 005 | 20090309 | ||
| 007 | t | ||
| 008 | 081015s2008 ad|| |||| 10||| und d | ||
| 035 | |a (OCoLC)635313799 | ||
| 035 | |a (DE-599)BVBBV035101291 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | |a und | ||
| 049 | |a DE-355 | ||
| 245 | 1 | 0 | |a Abstracts from the XXth International Symposium on Medicinal Chemistry |b August 31 - September 4 [2008], Vienna, Austria |
| 264 | 1 | |a Barcelona [u.a.] |b Prous Science |c 2008 | |
| 300 | |a 341 S. |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 0 | |a Drugs of the future |v 33 : Suppl. |v A | |
| 500 | |a Einzelaufnahme eines Zeitschr.-Bd. | ||
| 650 | 0 | 7 | |a Pharmazeutische Chemie |0 (DE-588)4132158-3 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)1071861417 |a Konferenzschrift |y 2008 |z Wien |2 gnd-content | |
| 689 | 0 | 0 | |a Pharmazeutische Chemie |0 (DE-588)4132158-3 |D s |
| 689 | 0 | |5 DE-604 | |
| 711 | 2 | |a International Symposium on Medicinal Chemistry |n 20 |d 2008 |c Wien |j Sonstige |0 (DE-588)6522451-6 |4 oth | |
| 856 | 4 | 2 | |m GBV Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016769272&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-016769272 | ||
Datensatz im Suchindex
| _version_ | 1804138063543140352 |
|---|---|
| adam_text | DRUGS OF TH R* ^*^T VOLUME 33, SUPPL. A, AUGUST 2008 ABSTRACTS FROM THE
XX TH INTERNATIONAL SYMPOSIUM ON MEDICINAL CHEMISTRY AUGUST 31 -
SEPTEMBER 4, VIENNA, AUSTRIA &OES THOMSON REUTERS DRUGS HE FU1 VOLUME
33, SUPPL. A, AUGUST 2008 XX TH INTERNATIONAL SYMPOSIUM ON MEDICINAL
CHEMISTRY OPENING LECTURE PLOO LIFE ON THE EDGE: THE NATURE AND ORIGINS
OF PROTEIN MISFOLDING DISEASES CHRIS DOBSON, UNIVERSITY OF CAMBRIDGE 1
PLENARY LECTURES PL01 CHEMICAL TOOLS FOR THE STUDY OF COMPLEX BIOLOGICAL
SYSTEMS BARBARA IMPERIALI, MASSACHUSETTS INSTITUTE OF TECHNOLOGY 1 PL02
DRUG DISCOVERY FOR NEGLECTED DISEASES PAUL HERRLING, NOVARTIS
INTERNATIONAL 2 PL03 STRATEGIES FOR THE DISCOVERY OF INNOVATIVE
THERAPEUTICS MAGID ABOU-GHARBIA, WYETH RESEARCH 2 AWARD LECTURES AL01
CHANGING PARADIGMS IN DRUG DISCOVERY HUGO KUBINYI, BASF SE 3 AL02
AUTOMATED OLIGOSACCHARIDE SYNTHESIS AS PLATFORM FOR VACCINE DEVELOPMENT
PETER SEEBERGER, ETH ZUERICH 3 AL03 EXPLORING CHEMICAL SPACE WITH
APTAMERS MICHAEL FAMULOK, UNIVERSITY OF BONN 4 AL04 NEW TOOLS FOR
MOLECULE MAKERS: EMERGING TECHNOLOGIES STEVEN V. LEY, UNIVERSITY OF
CAMBRIDGE 4 LECTURES L01 INTEGRATION OF FRAGMENT DERIVED STRUCTURE-BASED
DESIGN INTO THE DISCOVERY AND DEVELOPMENT OF SELECTIVE KINASE INHIBITORS
FOR TREATMENT OF HUMAN CANCERS GAVIN HIRST, SGX PHARMACEUTICALS 5 L02
FRAGMENT BASED LEAD DISCOVERY RODERICK E. HUBBARD, UNIVERSITY OF YORK 6
L03 SEARCH FOR TAXOID MIMICS USING DYNAMIC COMBINATORIAL
CHEMISTRYTARGETING TUBULIN CIAIRE LE MANACH, ICMMO 6 L04 FRAGMENT BASED
DRUG DISCOVERY: FROM FRAGMENT TO CLINIC DAVID REES, ASTEX TECHNOLOGY LTD
7 L05 CHEMICAL STRATEGIES FOR SUCCESSFUL CLINICAL DEVELOPMENT
CHRISTOPHER N. JOHNSON, GLAXOSMITHKUNE 7 L06 RECENT STRATEGIES AROUND
PREDICTING ORAL ABSORPTION DAVID MILLAN, PFIZER7 7 L07 DISCOVERY AND
DEVELOPMENT OF THE NOVEL ANTITHROMBOTIC AGENT RIVAROXABAN, SUSANNE
ROEHRIG, BAYER HEALTHCARE 8 L08 IDENTIFICATION AND DEVELOPMENT OF PI3K
INHIBITORS - PATH TO THE CLINIC CARLOS GARCIA-ECHEVERRIA, NOVARTIS
PHARMA 8 L09 DISCOVERY OF TMC278: A NEXT GENERATION NNRTI DRUG, HIGHLY
ACTIVE AGAINST HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 (HIV-1) JEROEME
GUILLEMONT, JOHNSON & JOHNSON PRD 8 L10 KINASE SELECTIVITY IN DRUG
DISCOVERY-THE CHALLENGES AND OPPORTUNITIES DENNIS POWELL, WYETH RESEARCH
9 L1 1 TITLE NOT AVAILABLE AT THE TIME OF PRINTING LOUIS LOMBARDO,
BRISTOL-MYERS SQUIBB 9 L12 CDK INHIBITION - SELECTIVITY ISSUES IN
PRINCIPLE AND IN PRACTICE ANDREW THOMAS, ASTRAZENECA R&D 9 L13
PREDICTIVE ADME: EXAMPLES FROM THE REAL WORLD? ANDREW MARK DAVIS,
ASTRAZENECA R&D 10 L14 VIRTUAL METHODS FOR PREDICTING OFF-TARGET
PHARMACOLOGY JORDI MESTRES, IMIM AND UNIVERSITAET POMPEU FABRA 10 L15
PREDICTING BRAIN TO BLOOD DRUG PARTITIONING: PROGRESS AND LIMITATIONS
GABRIELE CRUCIANI, UNIVERSITA DI PERUGIA 10 L16 PEG CONJUGATION IN DRUG
DEVELOPMENT AND DISCOVERY FRANCESCO M. VERONESE, UNIVERSITY OF PADOVA 10
L17 MULTIVALENCY OF POLYMER THERAPEUTICS USED FOR THE INTEGRATION OF
ANTI-ANGIOGENIC THERAPY WITH CHEMOTHERAPY RONIT SATCHI-FAIRANO, TEL AVIV
UNIVERSITY 11 L18 5 -PHOSPHATE MIMICS WITHIN ALTRITOL-MODIFIED SIRNAS
AND INHIBITION OF MDR1 EXPRESSION ARTHUR VAN AERSCHOT, KULEUVEN 12 L19
EVOLUTION: DESIGN AND IMPLEMENTATION OF A FRAGMENT DISCOVERY PLATFORM
JOHN BARKER, EVOTEC 12 L20 FRAGMENT-BASED DRUG DISCOVERY: WHAT HAS IT
ACHIEVED SO FAR? ALEXANDER ALEX, PFIZER .13 L21 FRAGMENT-BASED LEAD
GENERATION: CHALLENGES AND SUCCESSES. DISCOVERY OF HIGH AFFINITY
BETA-SECRETASE INHIBITORS JEFFREY ALBERT, ASTRAZENECA 13 L22 FLUOROMETRY
AND FRET IN MEASURING BIOMARKERS AND MONITORING CELL SIGNALLING CASCADE
LLKKA HEMMILA, PERKINELMER LIFE SCIENCES 13 L23 MASS SENSITIVE LIGANDS
USEFUL FOR BIOMARKER DISCOVERY AND VALIDATION PETER SCHULZ-KNAPPE,
PROTEOME SCIENCES 14 L24 DESIGN OF SPIN-LABELED SULFONAMIDES AS CARBONIC
ANHYDRASE INHIBITORS ALESSANDRO CECCHI, UNIVERSITY OF FLORENCE 1 4 L25
BIODIVERSE NATURAL PRODUCTS IN DRUG DISCOVERY DOUGLAS KINGHORN, OHIO
STATE UNIVERSITY 15 L26 HOW TO USE THE STRUCTURAL DIVERSITY OF NATURAL
PRODUCTS FOR DRUG DISCOVERY PHILIPP KRASTEL, NOVARTIS INSTITUTES FOR
BIOMEDICAL RESEARCH 15 L27 SELECTIVITY IN THE ANTIBACTERIAL ACTIVITY OF
MINOR GROOVE BINDERS, DERIVATIVES OF THE NATURAL PRODUCT, DISTAMYCIN
COLIN SUCKLING, UNIVERSITY OF STRATHCLYDE 16 L28 PROTEIN MISFOLDING AND
SELF-ASSEMBLY IN NEURODEGENERATIVE DISEASES HILAL A. LASHUEL, EPFL -
ECUBLENS 16 L29 APPROACHES TO THE TREATMENT OF COGNITIVE DYSFUNCTION AND
ALZHEIMERN DISEASE AI ROBICHAUD, WYETH RESEARCH 17 L30 HALOMETHYLKETONES
(HMKS): GSK-3 INHIBITORS WITH DISEASE-MODIFYING PROPERTIES FOR
ALZHEIMERS DISEASE THERAPY ANA MARTINEZ, INSTITUTO DE QUIMICA
MEDICA-CSIC 17 L31 DPP-4 INHIBITORS: GALVUS / VILDAGLIPTIN AND
FOLLOWING GENERATIONS DANIEL BAESCHLIN, NOVARTIS INSTITUTES FOR
BIOMEDICAL RESEARCH 17 L32 PEPTIDIC AND NON-PEPTIDIC GLUCAGON LIKE
PEPTIDE 1 RECEPTOR AGONISTS JESPERLAU, NOVO NORDISK 18 L33 DEVELOPMENT
OF DPP8/9 INHIBITORS PIETER VAN DER VEKEN, UNIVERSITY OF ANTWERP 18 L34
RECENT DEVELOPMENTS IN CCR3 ANTAGONIST GEORGE V. DE LUCCA, BRISTOL-MYERS
SQUIBB 18 L35 PI3KGAMMA INHIBITORS: ASPIRIN OF THE 21 ST CENTURY? THOMAS
RUECKLE, MERCK SERONO 19 L36 4-OXO-BETA-LACTAMS (AZETIDINE-2,4-DIONES)
BASED NOVEL POTENT INHIBITORS OF ELASTASE JALMIRA MULCHANDE, LISBON
UNIVERSTY 19 L37 THE POTENTIAL OF ALLOSTERIC MODULATION FOR GPCR DRUG
DISCOVERY ARTHUR CHRISTOPOULOS, MONASH UNIVERSITY. 20 L38 THERAPEUTIC
OPPORTUNITIES FOR SMALL MOLECULE MODULATORS OF CHEMOKINE RECEPTORS
THOMAS J. SCHALL, CHEMOCENTRYX 20 L39 HIGH-THROUGHPUT SCREENING OF
POTENTIAL DRUG CANDIDATES FOR GPR-17 RECEPTOR BY FAC-MS: DEVELOPMENT AND
APPLICATION OF A NEW GPR17 STATIONARY PHASE GABRIELLA MASSOLINI,
UNIVERSITY OF PAVIA 20 L40 THE DISCOVERY OF MK-0731: THE ROLE OF
FLUORINE IN OPTIMIZATION OF KINESIN SPINDLE PROTEIN (KSP) INHIBITORS FOR
THE TREATMENT OF CANCER PAUL COLEMAN, MERCK RESEARCH LABORATORIES 21 L41
ALLOSTERIC AKT INHIBITORS GEORGE HARTMAN, MERCK RESEARCH LABORATORIES 2
1 L42 BL 2536, DISCOVERY OF A POTENT AND HIGHLY SPECIFIC INHIBITOR OF
POLO-LIKE KINASE 1 MATTHIAS HOFFMANN, BOEHRINGER INGELHEIM 22 L43
CURRENT ASPECTS AND FUTURE TRENDS IN IMMUNOMODULATION MURRAY MCKINNON,
BRISTOL-MYERS SQUIBB 22 L44 ADVANCES IN TARGETING GLUCOCORTICOIDS MARKUS
BERGER, BAYER SCHERING PHARMA 22 L45 TARGET VALIDATION AND LEAD
IDENTIFICATION OF SELECTIVE CB2 RECEPTOR AGONISTS FOR THE TREATMENT OF
INFLAMMATION AND PAIN DORIS RIETHER, BOEHRINGER-INGELHEIM 23 L46 NK3
RECEPTOR ANTAGONISTS FOR THE TREATMENT OF SCHIZOPHRENIA - CHALLENGES AND
OPPORTUNITIES KLAUS SIMONSEN, H. LUNDBECK 23 L47 DEVELOPMENT OF MULTIPLE
STRUCTURAL LEAD OPTIONS UTILIZING STRUCTURE BASED DRUG DESIGN TO
IDENTIFY A PDE10 CLINICAL CANDIDATE TO TREAT SCHIZOPHRENIA SPIROS LIRAS,
PFIZER GLOBAL RESEARCH 24 L48 DOPAMINE SYSTEM STABILIZERS GYOERGY DOMANY,
GEDEON RICHTER PLC 24 L49 TARGETTING THE GLYCANS ON THE VIRAL ENVELOPE,
A NOVEL THERAPEUTIC CONCEPT JAN BALZARINI, REGA INSTITUTE FOR MEDICAL
RESEARCH 25 L50 LETHAL MUTAGENESIS AS A NEW ANTIVIRAL STRATEGY ESTEBAN
DOMINGO, UNIVERSIDAD AUTONOMA DE MADRID 25 L51 PROGRESS IN THE
DEVELOPMENT OF NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIS)
OF HIV: FROM TIBO TO RILPIVIRINE JAN HEERES, JANSSEN PHARMACEUTICA 26
L52 CHRONIC PAIN: NEW TARGETS STEFAN MCDONOUGH, AMGEN 26 L53 DISCOVERY
OF A SELECTIVE TRPV1 ANTAGONIST, AMG 517 MARK NORMAN, AMGEN 26 L54 NOVEL
ALPHA2DELTA LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN GRAHAM N. MAW,
PFIZER 27 L55 COMPUTER-ASSISTED MOLECULAR DESIGN: VOYAGES TO THE
(UN)KNOWN GISBERT SCHNEIDER, JOHANN WOLFGANG GOETHE UNIVERSITY 27 L56
THE QUEST FOR BIOISOSTERISM IN THE OTHER SIDE OF CHEMICAL SPACE
ANTONIO MACCHIARULO, UNIVERSITY OF PERUGIA 27 L57 EXPLORATION OF
CHEMICAL SPACE FOR DRUG DISCOVERY BY DATABASE GENERATION JEAN-LOUIS
REYMOND, UNIVERSITAET BERN 28 L58 SCAFFOLD HUNTER: CHARTING AND EXPLORING
CHEMICAL SPACE STEFAN WETZEL, MAX PLANCK INSTITUTE OF MOLECULAR
PHYSIOLOGY 28 L59 CXCR4 ANTAGONISTS: RELEVANCE TO CANCER CHEMOTHERAPY
NOBUTAKA FUJII, KYOTO UNIVERSITY 2 9 L60 CCR2 / CCR5 ANTAGONISTS: A NEW
APPROACH FOR THE TREATMENT OF AUTO-IMMUNE DISEASES WOLFGANG MILTZ,
NOVARTIS PHARMA 29 L61 BIOLOGICAL PROFILING OF ANTI-HIV AGENTS USING IN
SILICO TECHNIQUES: INSIGHTS INTO CCR5 LIGANDS BINDING THROUGH HOMOLOGY
BUILDINGS, 3D-QSAR, DOCKING AND SHAPE MATCHING VIRTUAL SCREENING ANTONIO
CARRIERI, DIPARTIMENTO FARMACO-CHIMICO 29 L62 MULTIMODALITY IMAGING BY
MR, PET, AND CT FOR THE STUDY OF ATHEROSCLEROSIS ZAHL A. FAYAD, MOUNT
SINAI SCHOOL OF MEDICINE 30 L63 PROFILING SH2 AND TYROSINE PHOSPHATASES
TARGET SPECIFICITY GIANNI CESARENI, UNIVERSITY OF ROME TOR VERGATA 30
L64 SYSTEMS LEVEL RESEARCH INFORMS DRUG TARGET IDENTIFICATION AND
THERAPY DESIGN HAREL WEINSTEIN, CORNELL UNIVERSITY 30 L65 OVERVIEW ON
NEW COMPUTATIONAL TOOLS SUPPORTING DRUG DESIGN TUDOR I. OPREA,
UNIVERSITY OF NEW MEXICO 31 L66 NOVEL OPEN SOURCE TOOLS FOR
CHEMICAL-BIOLOGICAL DATA GATHERING MUTHUKUMARASAMY KARTHIKEYAN, NATIONAL
CHEMICAL LABORATORY 31 L67 THE SCAFFOLD TREE - A NOVEL TOOLS FOR DATA
CLASSIFICATION ANSGAR SCHUFFENHAUER, NOVARTIS INSTITUTES FOR BIOMEDICAL
RESEARCH 32 L68 SHIFT : CHEMICAL STRUCTURE HOPPING BY ISOSTERIC FRAGMENT
TRANSFORMATIONS ELISABET GREGORI-PUIGJANE, CHEMOTARGETS 32 L69 TITLE NOT
AVAILABLE AT THE TIME OF PRINTING LEONARD J. PAGLIARO, THERMO FISHER
SCIENTIFIC, BIOIMAGE PRODUCTS 32 L70 RATIONAL DESIGN OF CYTOTOXIC
PEPTIDES FROM THE ANALYSIS OF PROTEIN-PROTEIN INTERACTIONS IN
MICROTUBULES STEFANO PIERACCINI, UNIVERSITA DEGLI STUDI DI MILANO 32
L71 PEPTIDOMIMETIC INHIBITORS OF THE PSD-95/NMDA RECEPTOR INTERACTION
ANDERS BACH, UNIVERSITY OF COPENHAGEN 33 L72 MAPPING THE BINDING SITE OF
SUBSTRATE TARGETING GAMMA-SECRETASE MODULATORS. PHASE III CANDIDATE FOR
ALZHEIMERS DISEASE UTILIZES A NOVEL PROTEIN-PROTEIN INTERACTION BORIS
SCHMIDT, TU DARMSTADT 33 L73 NETWORK-BASED DRUG DESIGN HANS WESTERHOFF,
VU UNIVERSITY AMSTERDAM 34 L74 SYSTEMS BIOLOGY - WHAT DOES IT MEAN FOR
PHARMACEUTICAL SCIENCE? CHRISTIAN NOE, UNIVERSITY OF VIENNA 34 L75
INTEGRATED APPROACH FOR THE MULTIRECEPTORIAL DESIGN OF ANTIPSYCHOTIC
AGENTS JANA SELENT, UNIVERSITAET POMPEU FABRA 35 L76 QUANTUM CHEMICAL
CALCULATION OF PROTEIN-LIGAND INTERACTION ISAO NAKANISHI, KYOTO
UNIVERSITY. 35 L77 ANALYSIS OF METAL ION TOXICITY IN ALZHEIMERN DISEASE
BY X-RAY STRUCTURAL STUDIES OF AMYLOID BETA AND COPPER ION INTERACTIONS
JOSE VARGHESE, CSIRO 36 L78 ACCESS AND BINDING OF LOCAL ANESTHETICS IN
THE CLOSED SODIUM CHANNEL IVA BRUHOVA, MCMASTER UNIVERSITY 36 L79
ENGINEERING OF PURINE RECEPTORS AND THEIR LIGANDS KENNETH A. JACOBSON,
NIDDK 37 L80 NEW MODULATORS OF A 3 AND A 2B ADENOSINE RECEPTORS PIER
GIOVANNI BARALDI, UNIVERSITY OF FERRARA 37 L81 ALLOSTERIC MODULATION OF
ADENOSINE RECEPTORS AD P. IJZERMAN, LEIDEN/AMSTERDAM CENTER FOR DRUG
RESEARCH 38 L82 ALTERNATIVES TO KINASE INHIBITORS FOR CANCER THERAPIES
GIOVANNI GAVIRAGHI, SIENA BIOTECH 38 L83 ENDOTHELIN CONVERTING ENZYME
INHIBITORS AS ANTICANCER AGENTS FOR HUMAN GLIOBLAS- TOMA. A COMPARISON
WITH ENDOTHELIN RECEPTOR ANTAGONISTS LUCIENNE JUILLERAT, CENTRE
HOSPITALIER UNIVERSITAIRE VAUDOIS 39 L84 IDENTIFICATION OF A SMALL
MOLECULE AKT KINASE INHIBITOR, SK690693 DIRK HEERDING, GLAXOSMITHKLINE
40 POSTERS 41 AUTHOR INDEX 323 THIS ABSTRACT BOOK HAS BEEN PRODUCED
USING ELECTRONIC SUBMISSIONS. EVERY EFFORT HAS BEEN MADE TO REPRODUCE
THE ABSTRACTS AS SUBMITTED AND AS RECEIVED BY THE PUBLISHER AT THE TIME
OF PRINTING. A SELECTED NUMBER OF PRESENTATIONS WILL BE AVAILABLE AS
WEBCASTS. VISIT HTTP://WWW.ISMC2008.ORG FOR DETAILS.
|
| adam_txt |
DRUGS OF TH R* ^*^T VOLUME 33, SUPPL. A, AUGUST 2008 ABSTRACTS FROM THE
XX TH INTERNATIONAL SYMPOSIUM ON MEDICINAL CHEMISTRY AUGUST 31 -
SEPTEMBER 4, VIENNA, AUSTRIA &OES THOMSON REUTERS DRUGS " HE FU1 VOLUME
33, SUPPL. A, AUGUST 2008 XX TH INTERNATIONAL SYMPOSIUM ON MEDICINAL
CHEMISTRY OPENING LECTURE PLOO LIFE ON THE EDGE: THE NATURE AND ORIGINS
OF PROTEIN MISFOLDING DISEASES CHRIS DOBSON, UNIVERSITY OF CAMBRIDGE 1
PLENARY LECTURES PL01 CHEMICAL TOOLS FOR THE STUDY OF COMPLEX BIOLOGICAL
SYSTEMS BARBARA IMPERIALI, MASSACHUSETTS INSTITUTE OF TECHNOLOGY 1 PL02
DRUG DISCOVERY FOR NEGLECTED DISEASES PAUL HERRLING, NOVARTIS
INTERNATIONAL 2 PL03 STRATEGIES FOR THE DISCOVERY OF INNOVATIVE
THERAPEUTICS MAGID ABOU-GHARBIA, WYETH RESEARCH 2 AWARD LECTURES AL01
CHANGING PARADIGMS IN DRUG DISCOVERY HUGO KUBINYI, BASF SE 3 AL02
AUTOMATED OLIGOSACCHARIDE SYNTHESIS AS PLATFORM FOR VACCINE DEVELOPMENT
PETER SEEBERGER, ETH ZUERICH 3 AL03 EXPLORING CHEMICAL SPACE WITH
APTAMERS MICHAEL FAMULOK, UNIVERSITY OF BONN 4 AL04 NEW TOOLS FOR
MOLECULE MAKERS: EMERGING TECHNOLOGIES STEVEN V. LEY, UNIVERSITY OF
CAMBRIDGE 4 LECTURES L01 INTEGRATION OF FRAGMENT DERIVED STRUCTURE-BASED
DESIGN INTO THE DISCOVERY AND DEVELOPMENT OF SELECTIVE KINASE INHIBITORS
FOR TREATMENT OF HUMAN CANCERS GAVIN HIRST, SGX PHARMACEUTICALS 5 L02
FRAGMENT BASED LEAD DISCOVERY RODERICK E. HUBBARD, UNIVERSITY OF YORK 6
L03 SEARCH FOR TAXOID MIMICS USING DYNAMIC COMBINATORIAL
CHEMISTRYTARGETING TUBULIN CIAIRE LE MANACH, ICMMO 6 L04 FRAGMENT BASED
DRUG DISCOVERY: FROM FRAGMENT TO CLINIC DAVID REES, ASTEX TECHNOLOGY LTD
7 L05 CHEMICAL STRATEGIES FOR SUCCESSFUL CLINICAL DEVELOPMENT
CHRISTOPHER N. JOHNSON, GLAXOSMITHKUNE 7 L06 RECENT STRATEGIES AROUND
PREDICTING ORAL ABSORPTION DAVID MILLAN, PFIZER7 7 L07 DISCOVERY AND
DEVELOPMENT OF THE NOVEL ANTITHROMBOTIC AGENT RIVAROXABAN, SUSANNE
ROEHRIG, BAYER HEALTHCARE 8 L08 IDENTIFICATION AND DEVELOPMENT OF PI3K
INHIBITORS - PATH TO THE CLINIC CARLOS GARCIA-ECHEVERRIA, NOVARTIS
PHARMA 8 L09 DISCOVERY OF TMC278: A NEXT GENERATION NNRTI DRUG, HIGHLY
ACTIVE AGAINST HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 (HIV-1) JEROEME
GUILLEMONT, JOHNSON & JOHNSON PRD 8 L10 KINASE SELECTIVITY IN DRUG
DISCOVERY-THE CHALLENGES AND OPPORTUNITIES DENNIS POWELL, WYETH RESEARCH
9 L1 1 TITLE NOT AVAILABLE AT THE TIME OF PRINTING LOUIS LOMBARDO,
BRISTOL-MYERS SQUIBB 9 L12 CDK INHIBITION - SELECTIVITY ISSUES IN
PRINCIPLE AND IN PRACTICE ANDREW THOMAS, ASTRAZENECA R&D 9 L13
PREDICTIVE ADME: EXAMPLES FROM THE REAL WORLD? ANDREW MARK DAVIS,
ASTRAZENECA R&D 10 L14 VIRTUAL METHODS FOR PREDICTING OFF-TARGET
PHARMACOLOGY JORDI MESTRES, IMIM AND UNIVERSITAET POMPEU FABRA 10 L15
PREDICTING BRAIN TO BLOOD DRUG PARTITIONING: PROGRESS AND LIMITATIONS
GABRIELE CRUCIANI, UNIVERSITA DI PERUGIA 10 L16 PEG CONJUGATION IN DRUG
DEVELOPMENT AND DISCOVERY FRANCESCO M. VERONESE, UNIVERSITY OF PADOVA 10
L17 MULTIVALENCY OF POLYMER THERAPEUTICS USED FOR THE INTEGRATION OF
ANTI-ANGIOGENIC THERAPY WITH CHEMOTHERAPY RONIT SATCHI-FAIRANO, TEL AVIV
UNIVERSITY 11 L18 5'-PHOSPHATE MIMICS WITHIN ALTRITOL-MODIFIED SIRNAS
AND INHIBITION OF MDR1 EXPRESSION ARTHUR VAN AERSCHOT, KULEUVEN 12 L19
EVOLUTION: DESIGN AND IMPLEMENTATION OF A FRAGMENT DISCOVERY PLATFORM
JOHN BARKER, EVOTEC 12 L20 FRAGMENT-BASED DRUG DISCOVERY: WHAT HAS IT
ACHIEVED SO FAR? ALEXANDER ALEX, PFIZER ' .13 L21 FRAGMENT-BASED LEAD
GENERATION: CHALLENGES AND SUCCESSES. DISCOVERY OF HIGH AFFINITY
BETA-SECRETASE INHIBITORS JEFFREY ALBERT, ASTRAZENECA 13 L22 FLUOROMETRY
AND FRET IN MEASURING BIOMARKERS AND MONITORING CELL SIGNALLING CASCADE
LLKKA HEMMILA, PERKINELMER LIFE SCIENCES 13 L23 MASS SENSITIVE LIGANDS
USEFUL FOR BIOMARKER DISCOVERY AND VALIDATION PETER SCHULZ-KNAPPE,
PROTEOME SCIENCES 14 L24 DESIGN OF SPIN-LABELED SULFONAMIDES AS CARBONIC
ANHYDRASE INHIBITORS ALESSANDRO CECCHI, UNIVERSITY OF FLORENCE 1 4 L25
BIODIVERSE NATURAL PRODUCTS IN DRUG DISCOVERY DOUGLAS KINGHORN, OHIO
STATE UNIVERSITY 15 L26 HOW TO USE THE STRUCTURAL DIVERSITY OF NATURAL
PRODUCTS FOR DRUG DISCOVERY PHILIPP KRASTEL, NOVARTIS INSTITUTES FOR
BIOMEDICAL RESEARCH 15 L27 SELECTIVITY IN THE ANTIBACTERIAL ACTIVITY OF
MINOR GROOVE BINDERS, DERIVATIVES OF THE NATURAL PRODUCT, DISTAMYCIN
COLIN SUCKLING, UNIVERSITY OF STRATHCLYDE 16 L28 PROTEIN MISFOLDING AND
SELF-ASSEMBLY IN NEURODEGENERATIVE DISEASES HILAL A. LASHUEL, EPFL -
ECUBLENS 16 L29 APPROACHES TO THE TREATMENT OF COGNITIVE DYSFUNCTION AND
ALZHEIMERN DISEASE AI ROBICHAUD, WYETH RESEARCH 17 L30 HALOMETHYLKETONES
(HMKS): GSK-3 INHIBITORS WITH DISEASE-MODIFYING PROPERTIES FOR
ALZHEIMERS DISEASE THERAPY ANA MARTINEZ, INSTITUTO DE QUIMICA
MEDICA-CSIC 17 L31 DPP-4 INHIBITORS: GALVUS / VILDAGLIPTIN AND
FOLLOWING GENERATIONS DANIEL BAESCHLIN, NOVARTIS INSTITUTES FOR
BIOMEDICAL RESEARCH 17 L32 PEPTIDIC AND NON-PEPTIDIC GLUCAGON LIKE
PEPTIDE 1 RECEPTOR AGONISTS JESPERLAU, NOVO NORDISK 18 L33 DEVELOPMENT
OF DPP8/9 INHIBITORS PIETER VAN DER VEKEN, UNIVERSITY OF ANTWERP 18 L34
RECENT DEVELOPMENTS IN CCR3 ANTAGONIST GEORGE V. DE LUCCA, BRISTOL-MYERS
SQUIBB 18 L35 PI3KGAMMA INHIBITORS: ASPIRIN OF THE 21 ST CENTURY? THOMAS
RUECKLE, MERCK SERONO 19 L36 4-OXO-BETA-LACTAMS (AZETIDINE-2,4-DIONES)
BASED NOVEL POTENT INHIBITORS OF ELASTASE JALMIRA MULCHANDE, LISBON
UNIVERSTY 19 L37 THE POTENTIAL OF ALLOSTERIC MODULATION FOR GPCR DRUG
DISCOVERY ARTHUR CHRISTOPOULOS, MONASH UNIVERSITY. 20 L38 THERAPEUTIC
OPPORTUNITIES FOR SMALL MOLECULE MODULATORS OF CHEMOKINE RECEPTORS
THOMAS J. SCHALL, CHEMOCENTRYX 20 L39 HIGH-THROUGHPUT SCREENING OF
POTENTIAL DRUG CANDIDATES FOR GPR-17 RECEPTOR BY FAC-MS: DEVELOPMENT AND
APPLICATION OF A NEW GPR17 STATIONARY PHASE GABRIELLA MASSOLINI,
UNIVERSITY OF PAVIA 20 L40 THE DISCOVERY OF MK-0731: THE ROLE OF
FLUORINE IN OPTIMIZATION OF KINESIN SPINDLE PROTEIN (KSP) INHIBITORS FOR
THE TREATMENT OF CANCER PAUL COLEMAN, MERCK RESEARCH LABORATORIES 21 L41
ALLOSTERIC AKT INHIBITORS GEORGE HARTMAN, MERCK RESEARCH LABORATORIES 2
1 L42 BL 2536, DISCOVERY OF A POTENT AND HIGHLY SPECIFIC INHIBITOR OF
POLO-LIKE KINASE 1 MATTHIAS HOFFMANN, BOEHRINGER INGELHEIM 22 L43
CURRENT ASPECTS AND FUTURE TRENDS IN IMMUNOMODULATION MURRAY MCKINNON,
BRISTOL-MYERS SQUIBB 22 L44 ADVANCES IN TARGETING GLUCOCORTICOIDS MARKUS
BERGER, BAYER SCHERING PHARMA 22 L45 TARGET VALIDATION AND LEAD
IDENTIFICATION OF SELECTIVE CB2 RECEPTOR AGONISTS FOR THE TREATMENT OF
INFLAMMATION AND PAIN DORIS RIETHER, BOEHRINGER-INGELHEIM 23 L46 NK3
RECEPTOR ANTAGONISTS FOR THE TREATMENT OF SCHIZOPHRENIA - CHALLENGES AND
OPPORTUNITIES KLAUS SIMONSEN, H. LUNDBECK 23 L47 DEVELOPMENT OF MULTIPLE
STRUCTURAL LEAD OPTIONS UTILIZING STRUCTURE BASED DRUG DESIGN TO
IDENTIFY A PDE10 CLINICAL CANDIDATE TO TREAT SCHIZOPHRENIA SPIROS LIRAS,
PFIZER GLOBAL RESEARCH 24 L48 DOPAMINE SYSTEM STABILIZERS GYOERGY DOMANY,
GEDEON RICHTER PLC 24 L49 TARGETTING THE GLYCANS ON THE VIRAL ENVELOPE,
A NOVEL THERAPEUTIC CONCEPT JAN BALZARINI, REGA INSTITUTE FOR MEDICAL
RESEARCH 25 L50 LETHAL MUTAGENESIS AS A NEW ANTIVIRAL STRATEGY ESTEBAN
DOMINGO, UNIVERSIDAD AUTONOMA DE MADRID 25 L51 PROGRESS IN THE
DEVELOPMENT OF NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIS)
OF HIV: FROM TIBO TO RILPIVIRINE JAN HEERES, JANSSEN PHARMACEUTICA 26
L52 CHRONIC PAIN: NEW TARGETS STEFAN MCDONOUGH, AMGEN 26 L53 DISCOVERY
OF A SELECTIVE TRPV1 ANTAGONIST, AMG 517 MARK NORMAN, AMGEN 26 L54 NOVEL
ALPHA2DELTA LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN GRAHAM N. MAW,
PFIZER 27 L55 COMPUTER-ASSISTED MOLECULAR DESIGN: VOYAGES TO THE
(UN)KNOWN GISBERT SCHNEIDER, JOHANN WOLFGANG GOETHE UNIVERSITY 27 L56
THE QUEST FOR BIOISOSTERISM IN THE "OTHER SIDE" OF CHEMICAL SPACE
ANTONIO MACCHIARULO, UNIVERSITY OF PERUGIA 27 L57 EXPLORATION OF
CHEMICAL SPACE FOR DRUG DISCOVERY BY DATABASE GENERATION JEAN-LOUIS
REYMOND, UNIVERSITAET BERN 28 L58 SCAFFOLD HUNTER: CHARTING AND EXPLORING
CHEMICAL SPACE STEFAN WETZEL, MAX PLANCK INSTITUTE OF MOLECULAR
PHYSIOLOGY 28 L59 CXCR4 ANTAGONISTS: RELEVANCE TO CANCER CHEMOTHERAPY
NOBUTAKA FUJII, KYOTO UNIVERSITY 2 9 L60 CCR2 / CCR5 ANTAGONISTS: A NEW
APPROACH FOR THE TREATMENT OF AUTO-IMMUNE DISEASES WOLFGANG MILTZ,
NOVARTIS PHARMA 29 L61 BIOLOGICAL PROFILING OF ANTI-HIV AGENTS USING IN
SILICO TECHNIQUES: INSIGHTS INTO CCR5 LIGANDS BINDING THROUGH HOMOLOGY
BUILDINGS, 3D-QSAR, DOCKING AND SHAPE MATCHING VIRTUAL SCREENING ANTONIO
CARRIERI, DIPARTIMENTO FARMACO-CHIMICO 29 L62 MULTIMODALITY IMAGING BY
MR, PET, AND CT FOR THE STUDY OF ATHEROSCLEROSIS ZAHL A. FAYAD, MOUNT
SINAI SCHOOL OF MEDICINE 30 L63 PROFILING SH2 AND TYROSINE PHOSPHATASES
TARGET SPECIFICITY GIANNI CESARENI, UNIVERSITY OF ROME 'TOR VERGATA' 30
L64 SYSTEMS LEVEL RESEARCH INFORMS DRUG TARGET IDENTIFICATION AND
THERAPY DESIGN HAREL WEINSTEIN, CORNELL UNIVERSITY 30 L65 OVERVIEW ON
NEW COMPUTATIONAL TOOLS SUPPORTING DRUG DESIGN TUDOR I. OPREA,
UNIVERSITY OF NEW MEXICO 31 L66 NOVEL OPEN SOURCE TOOLS FOR
CHEMICAL-BIOLOGICAL DATA GATHERING MUTHUKUMARASAMY KARTHIKEYAN, NATIONAL
CHEMICAL LABORATORY 31 L67 THE SCAFFOLD TREE - A NOVEL TOOLS FOR DATA
CLASSIFICATION ANSGAR SCHUFFENHAUER, NOVARTIS INSTITUTES FOR BIOMEDICAL
RESEARCH 32 L68 SHIFT : CHEMICAL STRUCTURE HOPPING BY ISOSTERIC FRAGMENT
TRANSFORMATIONS ELISABET GREGORI-PUIGJANE, CHEMOTARGETS 32 L69 TITLE NOT
AVAILABLE AT THE TIME OF PRINTING LEONARD J. PAGLIARO, THERMO FISHER
SCIENTIFIC, BIOIMAGE PRODUCTS 32 L70 RATIONAL DESIGN OF CYTOTOXIC
PEPTIDES FROM THE ANALYSIS OF PROTEIN-PROTEIN INTERACTIONS IN
MICROTUBULES STEFANO PIERACCINI, UNIVERSITA' DEGLI STUDI DI MILANO 32
L71 PEPTIDOMIMETIC INHIBITORS OF THE PSD-95/NMDA RECEPTOR INTERACTION
ANDERS BACH, UNIVERSITY OF COPENHAGEN 33 L72 MAPPING THE BINDING SITE OF
SUBSTRATE TARGETING GAMMA-SECRETASE MODULATORS. PHASE III CANDIDATE FOR
ALZHEIMERS DISEASE UTILIZES A NOVEL PROTEIN-PROTEIN INTERACTION BORIS
SCHMIDT, TU DARMSTADT 33 L73 NETWORK-BASED DRUG DESIGN HANS WESTERHOFF,
VU UNIVERSITY AMSTERDAM 34 L74 SYSTEMS BIOLOGY - WHAT DOES IT MEAN FOR
PHARMACEUTICAL SCIENCE? CHRISTIAN NOE, UNIVERSITY OF VIENNA 34 L75
INTEGRATED APPROACH FOR THE MULTIRECEPTORIAL DESIGN OF ANTIPSYCHOTIC
AGENTS JANA SELENT, UNIVERSITAET POMPEU FABRA 35 L76 QUANTUM CHEMICAL
CALCULATION OF PROTEIN-LIGAND INTERACTION ISAO NAKANISHI, KYOTO
UNIVERSITY. 35 L77 ANALYSIS OF METAL ION TOXICITY IN ALZHEIMERN DISEASE
BY X-RAY STRUCTURAL STUDIES OF AMYLOID BETA AND COPPER ION INTERACTIONS
JOSE VARGHESE, CSIRO 36 L78 ACCESS AND BINDING OF LOCAL ANESTHETICS IN
THE CLOSED SODIUM CHANNEL IVA BRUHOVA, MCMASTER UNIVERSITY 36 L79
ENGINEERING OF PURINE RECEPTORS AND THEIR LIGANDS KENNETH A. JACOBSON,
NIDDK 37 L80 NEW MODULATORS OF A 3 AND A 2B ADENOSINE RECEPTORS PIER
GIOVANNI BARALDI, UNIVERSITY OF FERRARA 37 L81 ALLOSTERIC MODULATION OF
ADENOSINE RECEPTORS AD P. IJZERMAN, LEIDEN/AMSTERDAM CENTER FOR DRUG
RESEARCH 38 L82 ALTERNATIVES TO KINASE INHIBITORS FOR CANCER THERAPIES
GIOVANNI GAVIRAGHI, SIENA BIOTECH 38 L83 ENDOTHELIN CONVERTING ENZYME
INHIBITORS AS ANTICANCER AGENTS FOR HUMAN GLIOBLAS- TOMA. A COMPARISON
WITH ENDOTHELIN RECEPTOR ANTAGONISTS LUCIENNE JUILLERAT, CENTRE
HOSPITALIER UNIVERSITAIRE VAUDOIS 39 L84 IDENTIFICATION OF A SMALL
MOLECULE AKT KINASE INHIBITOR, SK690693 DIRK HEERDING, GLAXOSMITHKLINE
40 POSTERS 41 AUTHOR INDEX 323 THIS ABSTRACT BOOK HAS BEEN PRODUCED
USING ELECTRONIC SUBMISSIONS. EVERY EFFORT HAS BEEN MADE TO REPRODUCE
THE ABSTRACTS AS SUBMITTED AND AS RECEIVED BY THE PUBLISHER AT THE TIME
OF PRINTING. A SELECTED NUMBER OF PRESENTATIONS WILL BE AVAILABLE AS
WEBCASTS. VISIT HTTP://WWW.ISMC2008.ORG FOR DETAILS. |
| any_adam_object | 1 |
| any_adam_object_boolean | 1 |
| building | Verbundindex |
| bvnumber | BV035101291 |
| ctrlnum | (OCoLC)635313799 (DE-599)BVBBV035101291 |
| format | Conference Proceeding Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01389nam a2200325 cb4500</leader><controlfield tag="001">BV035101291</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20090309 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">081015s2008 ad|| |||| 10||| und d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)635313799</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV035101291</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">und</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Abstracts from the XXth International Symposium on Medicinal Chemistry</subfield><subfield code="b">August 31 - September 4 [2008], Vienna, Austria</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Barcelona [u.a.]</subfield><subfield code="b">Prous Science</subfield><subfield code="c">2008</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">341 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Drugs of the future</subfield><subfield code="v">33 : Suppl.</subfield><subfield code="v">A</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Einzelaufnahme eines Zeitschr.-Bd.</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmazeutische Chemie</subfield><subfield code="0">(DE-588)4132158-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)1071861417</subfield><subfield code="a">Konferenzschrift</subfield><subfield code="y">2008</subfield><subfield code="z">Wien</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Pharmazeutische Chemie</subfield><subfield code="0">(DE-588)4132158-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="711" ind1="2" ind2=" "><subfield code="a">International Symposium on Medicinal Chemistry</subfield><subfield code="n">20</subfield><subfield code="d">2008</subfield><subfield code="c">Wien</subfield><subfield code="j">Sonstige</subfield><subfield code="0">(DE-588)6522451-6</subfield><subfield code="4">oth</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">GBV Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016769272&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-016769272</subfield></datafield></record></collection> |
| genre | (DE-588)1071861417 Konferenzschrift 2008 Wien gnd-content |
| genre_facet | Konferenzschrift 2008 Wien |
| id | DE-604.BV035101291 |
| illustrated | Illustrated |
| index_date | 2024-07-02T22:14:18Z |
| indexdate | 2024-07-09T21:22:14Z |
| institution | BVB |
| institution_GND | (DE-588)6522451-6 |
| language | Undetermined |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-016769272 |
| oclc_num | 635313799 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 341 S. Ill., graph. Darst. |
| publishDate | 2008 |
| publishDateSearch | 2008 |
| publishDateSort | 2008 |
| publisher | Prous Science |
| record_format | marc |
| series2 | Drugs of the future |
| spelling | Abstracts from the XXth International Symposium on Medicinal Chemistry August 31 - September 4 [2008], Vienna, Austria Barcelona [u.a.] Prous Science 2008 341 S. Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Drugs of the future 33 : Suppl. A Einzelaufnahme eines Zeitschr.-Bd. Pharmazeutische Chemie (DE-588)4132158-3 gnd rswk-swf (DE-588)1071861417 Konferenzschrift 2008 Wien gnd-content Pharmazeutische Chemie (DE-588)4132158-3 s DE-604 International Symposium on Medicinal Chemistry 20 2008 Wien Sonstige (DE-588)6522451-6 oth GBV Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016769272&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Abstracts from the XXth International Symposium on Medicinal Chemistry August 31 - September 4 [2008], Vienna, Austria Pharmazeutische Chemie (DE-588)4132158-3 gnd |
| subject_GND | (DE-588)4132158-3 (DE-588)1071861417 |
| title | Abstracts from the XXth International Symposium on Medicinal Chemistry August 31 - September 4 [2008], Vienna, Austria |
| title_auth | Abstracts from the XXth International Symposium on Medicinal Chemistry August 31 - September 4 [2008], Vienna, Austria |
| title_exact_search | Abstracts from the XXth International Symposium on Medicinal Chemistry August 31 - September 4 [2008], Vienna, Austria |
| title_exact_search_txtP | Abstracts from the XXth International Symposium on Medicinal Chemistry August 31 - September 4 [2008], Vienna, Austria |
| title_full | Abstracts from the XXth International Symposium on Medicinal Chemistry August 31 - September 4 [2008], Vienna, Austria |
| title_fullStr | Abstracts from the XXth International Symposium on Medicinal Chemistry August 31 - September 4 [2008], Vienna, Austria |
| title_full_unstemmed | Abstracts from the XXth International Symposium on Medicinal Chemistry August 31 - September 4 [2008], Vienna, Austria |
| title_short | Abstracts from the XXth International Symposium on Medicinal Chemistry |
| title_sort | abstracts from the xxth international symposium on medicinal chemistry august 31 september 4 2008 vienna austria |
| title_sub | August 31 - September 4 [2008], Vienna, Austria |
| topic | Pharmazeutische Chemie (DE-588)4132158-3 gnd |
| topic_facet | Pharmazeutische Chemie Konferenzschrift 2008 Wien |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016769272&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT internationalsymposiumonmedicinalchemistrywien abstractsfromthexxthinternationalsymposiumonmedicinalchemistryaugust31september42008viennaaustria |